The pharmaceuticals landscape is changing, in a positive way, and there is a growing appetite from both business and regulators for new technology and processes that can bring cost and sustainability savings. 

Becky’s decision to join HydRegen was motivated by her interest in being part of a startup’s dynamic and fast-paced environment. Attracted by the potential to take on diverse responsibilities to broaden her skill set and gain experience, she was also excited by the opportunity to witness and contribute to the company's growth. A decision that prompted her move from academia in the United States to the UK. 

At the core of HydRegen's mission to make chemical manufacturing safer and more sustainable lies a team of exceptional scientists dedicated to pushing the boundaries of biocatalysis. Among them is Yinqi, a biologist whose journey into the field has been driven by a passion for understanding and transforming the natural world. 

With HydRegen, I was immediately struck not only by the energy and ambition of the team, but also by the potential HydRegen technology has to make a real impact in the pharmaceutical sector and many others. Their innovative biocatalysis technology provides an efficient and sustainable alternative to traditional chemical manufacturing processes, and they have already started to demonstrate real world applications and impact.

HydRegen, the revolutionary bioscience company, is pleased to announce the appointment of John Boyle as a Scientist of Organic Chemistry. With more than 4 years’ experience in chemical biology and organic chemistry, John brings extensive knowledge of microbial biotransformation and recombinant enzymes.

HydRegen successfully completes tech transfer to Almac Sciences as part of the joint development project of its proprietary enzyme platform.